Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an update.
Shenzhen Hepalink Pharmaceutical Group has received approval from the National Medical Products Administration for a clinical trial of its new drug, H1710, designed to treat advanced solid tumors. H1710 is a novel heparanase inhibitor showing significant anti-tumor effects in preclinical studies, positioning the company at the forefront of developing unique anticancer therapies. However, the approval for clinical trials marks just the beginning, as there are inherent risks and uncertainties involved in the drug development process.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and commercialization of drugs, particularly in the area of oncology, with a market focus on innovative treatments for cancer.
YTD Price Performance: 0.25%
Average Trading Volume: 532,673
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$14.82B
See more data about 9989 stock on TipRanks’ Stock Analysis page.